

Initiator Pharma A/S: Trading in share options of series TO 1 will start on the 3rd of May

On the 3rd of May 2018, the trading in share options of series TO 1 in Initiator Pharma A/S ("Initiator Pharma") starts. The share options of series TO 1 was emitted in Initiator Pharma's rights issue of units in March 2018.

Summary of the terms of the share options

- Share options of series TO 1 will be traded on AktieTorget from the 3rd of May 2018.
- Holdings of one (1) share option of series TO 1 entitles to subscription of one (1) newly issued share at a price of SEK 2.20. Subscription of shares using share options is planned to take place during the period 11th of October 2018 through 1st of November 2018.
- Share options of series TO 1 has the ISIN-code DK0060954881.

Financial advisor

Sedermera Fondkommission has been the financial advisor to Initiator Pharma in connection with the rights issue of units.

For further information about the rights issue, please contact:

Sedermera Fondkommission
Telephone: +46 40-615 14 10
E-mail: info@sedermera.se

For further information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for patients suffering from Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond to the current market PDE5i medications. Learn more at initiatorpharma.com.

About erectile dysfunction

Erectile dysfunction is characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fuelled by aging demographics and increasing prevalence of life style diseases such as diabetes. The large diabetic ED patient segment is often responding poorly to the current medication and is therefore of particular interest for Initiator Pharma. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, relationship problems etc. (Althof, 2002; Shabsigh et al., 1998, Tsai, 2008; Litwin et al., 1998).

This is an English translation of a press release originally drafted in Swedish. In the case of any discrepancies, the Swedish version shall prevail.